Description
Introduction:
Sunitinib (SUTENT) is a medication used to treat cancer. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib Malate is an antineoplastic agent, Flk-1 inhibitor, and ATP-competitive inhibitor of PDGFR beta.
Intended Use:
This kit is used for quantitative estimation of Sunitinib in serum, plasma and cell culture supernatant using a competitive inhibition principle.
Principle:
The KRIBIOLISA Sunitinib ELISA is a competitive inhibition immunoassay for the determination of Sunitinib. The microplate is coated with VEGFA protein. VEGFA protein is a known dimeric glycoprotein which functions as a ligand for the receptor VEGFR2 (Flk1). Samples and standards containing Sunitinib is added to the plate with HRP conjugated VEGFR-2 from the kit simultaneously. The Sunitinib in the samples and standard will inhibit the binding of VEGFR-2 to the microplate. The amount of Sunitinib is inversely proportional to the color developed in the microplate post addition of TMB substrate and stopping the reaction. The absorbance is read at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!